Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.

about

Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.

Item

http://www.wikidata.org/entity/Q54166640

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@en

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@nl

type

Item

label

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@en

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@nl

prefLabel

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@en

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@nl

P1476

Management Strategies for Adve ...... in Non-Small Cell Lung Cancer.

@en

P2093

Paul Jennifer

http://www.w3.org/2001/XMLSchema#string

Wendy H Vogel

http://www.w3.org/2001/XMLSchema#string

P2860

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis

Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Cancer statistics, 2015

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

723-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29670808

http://www.w3.org/2001/XMLSchema#string

P932

5902152

http://www.w3.org/2001/XMLSchema#string